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Abstract
Background: Activation of blood coagulation and fibrinolysis may be associated with increased risk of coronary heart
disease. We aimed to assess associations of circulating tissue plasminogen activator (t-PA) antigen, D-dimer and von
Willebrand factor (VWF) with coronary heart disease risk.
Design: Prospective case-control study, systematic review and meta-analyses.
Methods: Measurements were made in 1925 people who had a first-ever nonfatal myocardial infarction or died of coronary
heart disease during follow-up (median 19.4 years) and in 3616 controls nested within the prospective population-based
Reykjavik Study.
Results: Age and sex-adjusted odds ratios for coronary heart disease per 1 standard deviation higher baseline level were
1.25 (1.18, 1.33) for t-PA antigen, 1.01 (0.95, 1.07) for D-dimer and 1.11 (1.05, 1.18) for VWF. After additional adjustment for
conventional cardiovascular risk factors, corresponding odds ratios were 1.07 (0.99, 1.14) for t-PA antigen, 1.06 (1.00, 1.13)
for D-dimer and 1.08 (1.02, 1.15) for VWF. When combined with the results from previous prospective studies in a random-
effects meta-analysis, overall adjusted odds ratios were 1.13 (1.06, 1.21) for t-PA antigen (13 studies, 5494 cases), 1.23 (1.16,
1.32) with D-dimer (18 studies, 6799 cases) and 1.16 (1.10, 1.22) with VWF (15 studies, 6556 cases).
Conclusions: Concentrations of t-PA antigen, D-dimer and VWF may be more modestly associated with first-ever CHD
events than previously reported. More detailed analysis is required to clarify whether these markers are causal risk factors or
simply correlates of coronary heart disease.
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Introduction
Because myocardial infarction usually results from occlusive
thrombosis of atherosclerotic plaque, it has been proposed that
circulating levels of markers that reflect activated coagulation and
fibrinolysis may be associated with coronary heart disease (CHD)
risk [1,2]. Three such markers are tissue plasminogen activator (t-
PA) antigen, D-dimer and von Willebrand factor (VWF). t-PA is
the principal regulator of endogenous fibrinolysis catalyzing the
conversion of plasminogen to plasmin [3]. In circulation, however,
most of t-PA is bound to its inhibitor PAI-1 (plasminogen activator
inhibitor type 1) and this complex can be measured as t-PA
antigen [4], with high levels indicating biologically inactive t-PA
and hence tendency to clot formation. D-dimer is a marker of
activated coagulation and fibrinolysis and its levels reflect active
fibrin mesh formation and degradation [5]. VWF is an important
cofactor in platelet adhesion and platelet aggregation, key steps in
primary hemostasis [6]. Previous studies have suggested significant
and moderately strong associations of these markers with CHD
risk in essentially general and secondary prevention populations
[7–9], with perhaps stronger associations for myocardial infarction
or fatal CHD than for incident stable angina, consistent with
potential roles for activation of coagulation and fibrinolysis in
coronary artery thrombosis, rather than atherogenesis [10]. To
date, however, the available evidence for t-PA antigen and D-
dimer has been limited to studies with only a few hundred CHD
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cases; insufficient to examine potentially important aspects such as
the shape of dose-response relationships and the magnitude of
these associations both overall and in clinically relevant subgroups
with appropriate power.
To help clarify these uncertainties, we report new data on t-PA
antigen and D-dimer involving 5541 participants in a prospective
case-control comparison nested within the population-based
Reykjavik Study of almost 19,000 middle aged Icelandic men
and women monitored for a mean duration of about 20 years
(results for VWF are presented here for comparison and have been
reported previously [11,12]). Context for our new data was
provided by conducting a systematic review and updated meta-
analyses of published reports on t-PA antigen, D-dimer and VWF
and incident CHD.
Methods
Study Population
The Reykjavik Study, initiated in 1967, has been described in
detail elsewhere [13]. All men born between 1907 and 1934 and
all women born between 1908 and 1935 who were registered to
live in Reykjavik, Iceland, or its adjacent communities on
December 1st 1966 were invited to participate in the study
(Figure S1). During five stages of recruitment between 1967 and
1991, a total of 9139 men and 9773 women were enrolled
(response rate = 72%). Nurses administered questionnaires, made
physical measurements, recorded electrocardiograms and col-
lected fasting venous blood samples for preparation of aliquots of
serum, which were stored at –20uC for subsequent analysis. All
participants were monitored by central registries for occurrence of
major coronary events (based on MONICA criteria [14]) or cause-
specific mortality (based on a death certificate with International
Classification of Diseases), with a loss to follow-up of only about
0.6% to date. Cause-specific mortality was coded using ICD-9 and
ICD-10. CHD deaths were pre-defined as those allocated ICD-9
codes 410–414 and ICD-10 codes I20–I25. We selected 1925
participants who suffered a first-ever non-fatal MI or coronary
death between study entry and the censoring date (median
duration of follow-up, 19.4 years) and without evidence of
cardiovascular disease at baseline, in whom baseline serum was
available for measurement of t-PA antigen, D-dimer and VWF.
We selected a random subset of 3616 controls from among the
participants who had survived to the end of the study period
without developing CHD, frequency matched to cases by
recruitment year, age (in five-year age bands) and sex. Baseline
characteristics of selected controls were broadly comparable to
those of the overall Reykjavik cohort (Table S1). The National
Bioethics Committee and the Data Protection Authority of Iceland
approved the study protocol. All participants gave informed
written consent and the study complies with the Declaration of
Helsinki.
Laboratory Methods
All measurements were made in serum samples, by laboratory
staff unaware of participants’ disease status. Enzyme immunoas-
says were used to determine levels of t-PA antigen (Biopool AB,
Umea, Sweden), D-dimer (Hyphen, Paris, France) and VWF (in-
house assay using reagents from DAKO, Copenhagen, Denmark).
All intra- and inter-assay coefficients of variation were,5%. Lipid
and other biochemical measurements have been described
previously [11–13].
Statistical Analyses
All analyses were restricted to participants with complete
information on t-PA antigen, D-dimer and VWF. Normal
distributions were achieved by taking natural logarithms (loge) of
positively skewed variables. Odds ratios (ORs) per 1 standard
deviation (SD) higher loge t-PA antigen, loge D-dimer and loge
VWF were calculated using unconditional logistic regression. The
Figure 1. Study flow diagram of the updated meta-analyses.
The figure was designed based on the 2009 PRISMA flow diagram
template (available from http://www.prisma-statement.org/statement.
htm).
doi:10.1371/journal.pone.0055175.g001
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SDs for baseline levels of loge t-PA antigen, loge D-dimer and loge
VWF were 0.5, 1.0 and 0.4, corresponding to 1.6-, 2.7- and 1.5-
fold differences on the original scale (ie, e0.5, e1.0 and e0.4). To assess
the independence of associations from conventional cardiovascular
risk factors, ORs were adjusted progressively for age, sex, period of
recruitment, smoking, body mass index, history of diabetes,
systolic blood pressure, total cholesterol and loge triglycerides.
To assess shapes of associations, adjusted ORs were calculated
across fifths of the baseline levels of t-PA antigen, D-dimer and
VWF in controls and 95% confidence intervals (CIs) were
estimated from the floated variances [15]. Subgroup analyses
were pre-specified and investigated by formal tests of interaction.
Linear regression was used to assess the association between t-PA
antigen, D-dimer and VWF and baseline characteristics among
controls. To minimize biases resulting from measurement error,
we corrected for regression dilution in supplementary analyses.
Regression dilution ratios (RDR), as a measure of long-term
within-person variability, were calculated for each characteristic
by regressing its serial measurements on baseline levels, adjusted
for potential confounding factors [16]. Based on these regression
models, predictions of long-term average levels (‘‘usual levels’’) of t-
PA antigen, D-dimer and VWF for each participant were then
used to estimate ORs corrected for within-person variability, as
described previously [16]. An updated meta-analysis was con-
ducted of prospective studies, published before October 19th 2012,
with more than one year of follow-up in essentially general
populations (ie, in cohorts not selected on the basis of pre-existing
disease) (Figure 1, Methods S1, Figure S2 and Table S2). To
enable comparability between study reports, risk estimates and
95% CIs were transformed to a common scale (ie, per 1 SD higher
levels of the population’s baseline distribution of the respective
marker) using methods previously described [11]. Study-specific
risk estimates were pooled by random-effects meta-analyses. Odds
and hazard ratios were assumed to approximate the same
underlying measure of relative risk (RR). Consistency of findings
across studies was assessed with standard x2 tests and the I2 statistic
[17]. Subgroup analyses were conducted using meta-regression
across pre-specified study-level characteristics [18]. Evidence of
publication bias was assessed with funnel plots, Egger’s test [19],
and by comparing pooled results from studies involving at least
500 CHD cases with pooled results from smaller studies. All
analyses were performed using Stata release 12.1 (StataCorp,
College Station, Texas). Statistical tests were two-sided and used a
significance level of P,0.05.
Results
Baseline Characteristics and Cross-sectional Associations
in the Reykjavik Study
In addition to significant differences between cases and controls
with respect to conventional risk factors in the Reykjavik Study,
baseline concentrations of t-PA antigen and VWF were signifi-
cantly higher in cases than in controls, while there were no
significant differences in D-dimer concentration (Table 1).
Baseline levels of t-PA antigen, D-dimer and VWF were
significantly correlated with each other, with t-PA antigen and
D-dimer being inversely associated (Table 1 and Figures S3 to
S5). All three markers were positively associated with age, smoking
and inflammatory markers. Male sex and baseline measurements
of body mass index, blood pressure, total cholesterol, loge
triglycerides, hematocrit, hemoglobin and loge erythrocyte sedi-
mentation rate showed positive correlations with levels of t-PA
antigen, but negative correlations with D-dimer. In comparison,
age- and sex-adjusted cross-sectional correlations of VWF were
generally weaker.
Associations with Incident CHD in the Reykjavik Study
After adjustment for age, sex and period of recruitment,
baseline levels of t-PA antigen were apparently log-linearly related
to CHD risk (Figure 2), yielding an OR of 1.25 (1.18, 1.33) per 1
SD higher level (Table 2). This OR fell to 1.07 (0.99, 1.14) after
further adjustment for several non-lipid and lipid risk factors.
VWF was also log-linearly associated with CHD risk (OR=1.11
[1.05, 1.18] minimally adjusted; 1.08 [1.02, 1.15] further
adjusted). However, there was no evidence of a significant
association between baseline levels of D-dimer and CHD risk
(OR=1.01 [0.95, 1.07] minimally adjusted; 1.06 [1.00, 1.13]
further adjusted). In a head-to-head comparison, t-PA antigen, D-
dimer and VWF were more weakly associated with incident CHD
than several established and emerging markers (Figure 3). ORs
did not vary substantially when further adjustment was made for
C-reactive protein (Table 2). Apart from a possibly weaker
association of t-PA antigen in current smokers compared with non-
smokers (P = 0.003), ORs for CHD did not vary in clinically
relevant subgroups defined by diabetes status, lipids, obesity, or
other individual-level characteristics (Figure S6).
Correction for Long-term within-person Variability
In up to 371 participants who provided paired measurements at
baseline and a mean (SD) of 11.6 (1.3) years later, age- and sex-
adjusted RDRs were 0.47 (95% CI 0.38, 0.56) for t-PA antigen,
0.30 (0.22, 0.38) for D-dimer and 0.55 (0.47, 0.63) for VWF
(Table S3). The within-person variability over 11.6 years in the
current study was somewhat greater than reported in previous
studies with measurements taken 5 or fewer years apart (p#0.007
for trend with time, Figure S7). After correction for within-person
variability in levels of the exposures, the ORs per 1 SD higher level
were 1.15 (1.01, 1.32) for t-PA antigen, 1.11 (0.99, 1.25) for D-
dimer 1.10 (1.03, 1.19) for VWF.
Systematic Review and Updated Meta-analyses
Together with the current study, 21 relevant published
prospective studies were identified (13 with t-PA antigen, 18 with
D-dimer and 15 with VWF measurement) [7–10,20–40]. Study
characteristics and references are provided in Table 3. All but one
were based in the United States or Europe. Most identified
participants in population registers or in occupational settings and
reported on incident MI or CHD death outcomes (mean follow-up
ranged from about 2.4 to 19.4 years). Measurements generally
involved enzymatic immunoassays, performed in plasma (17
studies) or serum (4 studies), thawed after long-term storage at
220uC (4 studies), 240uC (1 study), 270 or 280uC (14 studies) or
in liquid nitrogen (2 studies). Reported levels of t-PA antigen and
VWF were consistent across studies, while levels of D-dimer varied
substantially (ranging from around 10 to over 600 IU/dL). A
combined analysis of available data yielded adjusted RRs of 1.13
(1.06, 1.21), 1.23 (1.16, 1.32) and 1.16 (1.10, 1.22) per 1 SD higher
baseline levels of t-PA antigen (5494 CHD cases), D-dimer (6799
CHD cases) and VWF (6556 CHD cases), respectively (Figure 4).
There was some evidence of heterogeneity in RRs, but little of it
was explained by recorded study-level characteristics (Figure S9).
There was some evidence that smaller studies of D-dimer reported
more striking findings (Egger’s test, P=0.004; Figure S10), but
this trend was not apparent when results from studies with 500
CHD cases or more were compared with those from smaller
studies in the pre-specified subgroup analyses (Figure S9).
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Figure 2. Associations of baseline t-PA antigen, D-dimer and VWF with coronary heart disease risk (Reykjavik Study). Odds ratios
(95% CI) for coronary heart disease are shown by fifths of baseline t-PA antigen, D-dimer and VWF, plotted against the geometric mean level in each
category on a log-doubling scale. *Adjusted for age, sex, period of recruitment, smoking status, body mass index, systolic blood pressure, history of
diabetes, total cholesterol and loge triglycerides.
doi:10.1371/journal.pone.0055175.g002
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Discussion
In the Reykjavik Study, the largest population-based study of t-
PA antigen, D-dimer and VWF to date, we observed at most weak
associations of these markers with the risk of CHD, when adjusting
for a panel of conventional cardiovascular risk factors. However,
in the context of the updated meta-analyses that involved up to ten
times as much data as previously reported [7–9], higher levels of t-
PA antigen, D-dimer and VWF at baseline were compatible with
modest increases in risk. As suggested by previous reports, while t-
PA antigen was positive associated with various risk factors,
including male sex, blood pressure, body mass index, triglycerides,
inflammatory markers and rheological markers [9,20], D-dimer
was inversely associated with these risk factors and also inversely
associated with t-PA antigen levels [7]. This inverse association
could arise because t-PA antigen levels largely reflect circulating t-
PA/PAI-1 complexes, and higher PAI-1 levels reduce endogenous
fibrinolysis and hence D-dimer levels. Finally, baseline VWF levels
were largely independent from other cardiovascular risk factors
(with weak correlations with C-reactive protein and smoking
status).
Although the combined estimates from the current study and
previous reports were compatible with modest increases in risk, the
relationships of these three markers with CHD risk remain
uncertain, as evidenced by: the comparatively wide confidence
intervals around the pooled RRs; a tendency for more extreme
associations in smaller studies suggesting the likelihood of some
exaggeration in the overall estimates; and most importantly,
potential residual confounding, as the meta-analyses pooled
associations adjusted for baseline levels of confounders only [41].
The associations of t-PA antigen, D-dimer and VWF with first-
ever MI or CHD death may therefore be more modest than
previously reported, but the current findings do not, of course,
preclude stronger associations in high-risk populations [42,43] or
with different vascular outcomes [44,45].
To help clarify whether activated coagulation and fibrinolysis
play an etiological role in the development of CHD, future
investigations should involve complementary approaches to help
judge causality, such as study of potential interrelations with
ABO(H) blood groups [46,47]; investigation of more direct
markers such as t-PA activity or VWF multimer patterns [6];
Table 2. Association of baseline levels of t-PA antigen, D-dimer and VWF with coronary heart disease in the Reykjavik Study (1925
cases, 3616 controls).
Adjustment Odds ratios for coronary heart disease (95% CI) per 1 SD higher level
t-PA antigen D-dimer VWF
Adjusted for age, sex and period of recruitment 1.25 (1.18, 1.33) 1.01 (0.95, 1.07) 1.11 (1.05, 1.18)
+ non-lipid risk factors* 1.14 (1.07, 1.22) 1.04 (0.98, 1.10) 1.08 (1.02, 1.15)
+ lipid risk factors{ 1.07 (0.99, 1.14) 1.06 (1.00, 1.13) 1.08 (1.02, 1.15)
*Smoking status, body mass index, systolic blood pressure and any history of diabetes mellitus at baseline.
{Total cholesterol and loge triglycerides.
When analyses were restricted to participants with complete information on C-reactive protein (1906 cases, 3573 controls), the odds ratios (95% CI) per 1 SD higher
value of t-PA antigen were 1.26 (1.18, 1.33) when adjusting for age, sex and period of recruitment, 1.15 (1.07, 1.22) when additionally adjusting for non-lipid risk factors,
1.07 (0.99, 1.14) when additionally adjusting for lipid risk factors and 1.04 (0.97, 1.11) when additionally adjusting for C-reactive protein. Corresponding odds ratios were
1.01 (0.95, 1.07), 1.04 (0.98, 1.11), 1.07 (1.00, 1.14) and 1.05 (0.99, 1.12) for D-dimer and 1.12 (1.05, 1.18), 1.09 (1.02, 1.15), 1.09 (1.03, 1.16) and 1.06 (1.00, 1.13) for VWF.
doi:10.1371/journal.pone.0055175.t002
Figure 3. Head-to-head comparison of associations of various baseline variables with coronary heart disease risk (Reykjavik Study).
*Values were loge transformed for analysis. {Adjusted for age, sex, period of recruitment, smoking status, body mass index, systolic blood pressure,
history of diabetes, total cholesterol and loge triglycerides.
doi:10.1371/journal.pone.0055175.g003
Hemostatic Factors and CHD Risk
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Figure 4. Meta-analyses of reported associations of t-PA antigen, D-dimer and VWF with coronary heart disease risk in prospective
population-based studies. Study acronyms are explained in the legend of Table 3. Summary estimates were calculated using random effects
models. *Degree of adjustment:+minimally adjusted (typically adjusted for age and sex only);++plus adjustment for at least one non-lipid
marker;+++plus adjustment for at least one lipid marker;++++plus adjustment for at least one inflammatory marker. Where studies reported relative
risks with more than one level of statistical adjustment, the most adjusted estimate was used (least adjusted estimates are reported in Figure S8).
doi:10.1371/journal.pone.0055175.g004
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and mendelian randomization studies using genetic variants as
potentially unconfounded proxies for circulating levels of these
markers [48–51]. In particular, VWF levels may be a plausible
mediator of the association of non-O blood groups with CHD and
other thrombotic disorders [52].
Furthermore, the within-person variability of these hemostatic
markers is greater than previously reported and highlights the
importance of correction for variability in long-term prospective
studies and the potential advantages of identifying genetic variants
as proxies for these error-prone biomarkers [53]. While literature-
based data indicate a declining self-correlation over time,
suggesting that single ‘‘snapshot’’ baseline measurements do not
perfectly capture long-term ‘‘usual’’ levels, the magnitude of this
remains to be determined in detail. Information on the repeat-
ability of such measurements over time is currently available on
only around 2000 individuals in aggregate and is based
predominantly on summary findings from published reports and
not individual data.
The strengths and limitations of the current report merit careful
consideration. Our new data from the Reykjavik Study involve
more than three times as many cases of first-ever CHD as in the
previous largest reports [7–9]. Participants were identified in
population registers, had high response and follow-up rates, used
robust methods to ascertain CHD outcomes and minimized
potential biases by exclusion of participants with prevalent
cardiovascular disease. Concomitant measurements of several
factors enabled direct comparisons with different markers and
allowed adjustment for a range of possible confounders, although
we acknowledge that data on some biological factors was lacking
[54,55]. Repeat measurements several years apart enabled assess-
ment of and allowance for long-term within-person variability, but
no data were available to account for short-term variability, such as
diurnal or seasonal fluctuations [53,56]. Although the current study
involved blood storage at 220uC for a median time of 29 years
(range 4 to 33 years), the distributions of t-PA antigen, D-dimer and
VWF were broadly in keeping with those reported previously, as
exemplified by theWHO-MONICA optional Haemostasis Study of
11 centers across Europe that also included Iceland [57].
Furthermore, the generally similar correlations at baseline with
cardiovascular risk factors in this and other studies, plus the lack of
any significant heterogeneity in associations with CHD risk across
studies with different lengths of follow-up or sample storage
conditions in the updated meta-analyses, argues against sample
degradation as an explanation for our findings. Finally, although the
updated meta-analyses included in our report represent the most
comprehensive synthesis of the available data to date, they rely on
published reports only. Access to individual participant data would
permit more consistent comparisons across studies (such as in the
outcomes, covariates and subgroups considered).
Conclusions
Concentrations of t-PA antigen, D-dimer and VWF may be
more modestly associated with first-ever CHD events than
previously reported. More detailed analysis is required to clarify
whether these markers are causal risk factors or simply correlates
of coronary heart disease.
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